JP2023510332A5 - - Google Patents
Info
- Publication number
- JP2023510332A5 JP2023510332A5 JP2022542294A JP2022542294A JP2023510332A5 JP 2023510332 A5 JP2023510332 A5 JP 2023510332A5 JP 2022542294 A JP2022542294 A JP 2022542294A JP 2022542294 A JP2022542294 A JP 2022542294A JP 2023510332 A5 JP2023510332 A5 JP 2023510332A5
- Authority
- JP
- Japan
- Prior art keywords
- reducing
- metabolism
- agent
- methyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959514P | 2020-01-10 | 2020-01-10 | |
| US62/959,514 | 2020-01-10 | ||
| PCT/US2021/012447 WO2021142083A1 (en) | 2020-01-10 | 2021-01-07 | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510332A JP2023510332A (ja) | 2023-03-13 |
| JP2023510332A5 true JP2023510332A5 (enExample) | 2024-01-16 |
| JP7728264B2 JP7728264B2 (ja) | 2025-08-22 |
Family
ID=74418549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542294A Active JP7728264B2 (ja) | 2020-01-10 | 2021-01-07 | シトクロムｐ４５０の阻害剤を用いて３－（（メチルスルホニル）アミノ）－２－（（（４－フェニルシクロヘキシル）オキシ）メチル）ピペリジン－１－カルボン酸メチルまたはその塩の薬物動態を改善するまたは血漿中濃度を上昇させる方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12594269B2 (enExample) |
| EP (1) | EP4087534A1 (enExample) |
| JP (1) | JP7728264B2 (enExample) |
| KR (1) | KR20220127245A (enExample) |
| CN (1) | CN115226390B (enExample) |
| AU (1) | AU2021205892B2 (enExample) |
| BR (1) | BR112022013547A2 (enExample) |
| CA (1) | CA3167050A1 (enExample) |
| MX (1) | MX2022008392A (enExample) |
| WO (1) | WO2021142083A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020394444B2 (en) | 2019-11-25 | 2025-05-29 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN119968355A (zh) | 2022-10-07 | 2025-05-09 | 橘生药品工业株式会社 | 环戊烷化合物 |
| KR20250085056A (ko) | 2023-12-05 | 2025-06-12 | 안희태 | 국궁 과녁에서 영역 구분 센서의 구성 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317270A1 (en) * | 2000-09-08 | 2003-06-11 | Pharmacia Italia S.p.A. | Exemestane for the treatment of oestrogen-dependent cancers |
| EP2968341A4 (en) | 2013-03-14 | 2016-11-23 | Pharmacyclics Llc | COMBINATIONS OF BURTON TYROSINE KINASE INHIBITORS AND CYP3A4 INHIBITORS |
| EP4438041A3 (en) | 2016-02-04 | 2025-01-01 | Takeda Pharmaceutical Company Limited | Substituted piperidine compound and use thereof |
| JP6764017B2 (ja) | 2016-08-04 | 2020-09-30 | ギリアード サイエンシーズ， インコーポレイテッド | がんの処置での使用のためのコビシスタット |
| KR20220062361A (ko) | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| US20220339143A1 (en) | 2019-09-13 | 2022-10-27 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2021
- 2021-01-07 WO PCT/US2021/012447 patent/WO2021142083A1/en not_active Ceased
- 2021-01-07 US US17/791,302 patent/US12594269B2/en active Active
- 2021-01-07 EP EP21702564.2A patent/EP4087534A1/en active Pending
- 2021-01-07 JP JP2022542294A patent/JP7728264B2/ja active Active
- 2021-01-07 BR BR112022013547A patent/BR112022013547A2/pt unknown
- 2021-01-07 KR KR1020227023475A patent/KR20220127245A/ko active Pending
- 2021-01-07 CA CA3167050A patent/CA3167050A1/en active Pending
- 2021-01-07 MX MX2022008392A patent/MX2022008392A/es unknown
- 2021-01-07 CN CN202180017795.5A patent/CN115226390B/zh active Active
- 2021-01-07 AU AU2021205892A patent/AU2021205892B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12268723B2 (en) | Peptidomimetics for the treatment of coronavirus and picorna virus infections | |
| Das et al. | A survey of the structures of US FDA approved combination drugs | |
| US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| JP2023541430A5 (enExample) | ||
| JP2024075655A5 (ja) | 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用 | |
| Ghosh et al. | Drug delivery to the oral cavity: molecules to market | |
| JP4832045B2 (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| TW200916103A (en) | Therapeutic compositions and methods | |
| JP2022514089A5 (enExample) | ||
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| NZ594618A (en) | Transdermal pharmaceutical preparations | |
| JP2006504795A5 (enExample) | ||
| US20210386858A1 (en) | Mucoadhesive compositions and uses thereof | |
| JP2006508953A5 (enExample) | ||
| JP2019515909A5 (enExample) | ||
| JP2016528240A (ja) | ドルテグラビル、エムトリシタビン及びテノホビルの医薬コンビネーションを有する医薬 | |
| JP2013536837A5 (enExample) | ||
| JP2005508963A5 (enExample) | ||
| MX2007006343A (es) | Forma farmaceutica multiparticulada que comprende ingredientes activos de acido nucleico mucoadhesivamente formulado y un proceso para producir la forma farmaceutica. | |
| TW201414508A (zh) | 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式 | |
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| JP2010500284A5 (enExample) | ||
| JP2004538319A5 (enExample) | ||
| JP2023512025A5 (enExample) | ||
| JP2006503095A5 (enExample) |